Search Results for: SPM

15. Insights from the Metagenics Lifestyle Summit 2015 in Phoenix, AZ: Charles Serhan, PhD In this short video, Dr. Charles Serhan discusses the differences between specialized pro-resolving mediators (SPMs) formulations for clinical application. He indicates that different product formulations must be assessed for efficacy for specific uses. Further, SPMs themselves are natural molecules and are not all created equally. They are tissue-specific, so some promote tissue regeneration while others are more effective at phagocytosis, for example.

Specialized Pro-resolving Mediators (SPMs) in Real World Clinical Practice presented by Jennifer Stagg, ND Jennifer Stagg, ND, is a healthcare practitioner in Connecticut who actively uses nutritional solutions to help her patients achieve better health. She frequently sees patients who are experiencing chronic inflammation. In this webinar, she describes her experience seeing patients who have conditions that involve chronic inflammation and the solutions she uses to manage the underlying inflammation and the condition itself. We know that chronic inflammation is…

Real World Clinical Experiences with SPMs presented by Cory Rice, DO This presentation by Dr. Cory Rice is entitled “Specialized Pro-resolving Mediators in Real World Clinical Practice.” This is part of our peer-to-peer knowledge sharing series. Incorporating SPMs in clinical practice for patients with chronic disease, particularly those who need nutritional support for lifestyle medicine. Dr. Rice also provides several patient case studies in which he describes how SPMs have provided improved health outcomes to his patients. As we know,…

In the 2nd part of a new SPM interview series, Charles Serhan, PhD, DSc answers the question: “Can you describe some therapeutic areas where specialized pro-resolving mediators are currently being investigated for clinical use?” Dr. Serhan discusses the most current therapeutic research assessing SPM efficacy, including pulmonary, cardiometabolic, vascular, joint and cognitive health, as well as pain and wound healing. Charles Serhan, PhD, DSc is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital…

In the 3rd part of a new SPM interview series, Charles Serhan, PhD, DSc answers the question: “Are there any recent findings or results in resolvins research that have surprised you?” Dr. Serhan discusses the recently discovered resolution role of specialized pro-resolving mediators (SPMs) in the adaptive immune response, including the regulation of B cell function and facilitating antibody production. Charles Serhan, PhD, DSc is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital…

In the 4th part of the SPM interview series with Charles Serhan, PhD, DSc, he answers the question: “Besides peripheral blood, can pro-resolving mediators be measured in other tissues? If so, which ones?” Dr. Serhan shares current research findings on SPM measurement in the human body, demonstrating several human tissues and fluids where SPMs have been found. These discoveries will directly inform analytical methods for SPM measurement moving forward. Dr. Serhan also discusses the “coagulation clock”, as well as gender-…

In the 5th part of the SPM interview series with Charles Serhan, PhD, DSc, he explores the latest research to answer the question: “What is the role of resolvins in cancer?” Listen in as Dr. Serhan shares the impact resolvins have  on tumor debris clearance, tumor burden and cytotoxic agent use in animal models, as well as the potential for applications in human oncologic treatment. Charles Serhan, PhD, DSc is Director of the Center for Experimental Therapeutics and Reperfusion Injury…

In the 6th part of the SPM interview series, Charles Serhan, PhD, DSc provides insights into the query: “What role do you envision lipid mediators and active resolution will play in future clinical decision-making?” Dr. Serhan shares an edifying history on resolvins, from molecular work following their discovery in 2000, to the growing body of in vivo animal model results in inflammatory and infection processes, and now to the ongoing human clinical studies. Charles Serhan, PhD, DSc is Director of the…

Pathology & Prevalence of Asthma Asthma is a common chronic respiratory disorder that is characterized by “asthma attacks” during which airflow is obstructed. The Centers for Disease Control and Prevention report that in the prevalence of asthma among children is 8.6% and among adults is 7.4%. While boys are likelier than girls to have asthma, adult women are almost twice as likely to have asthma than are adult men. African Americans have the highest prevalence of asthma, at 9.9%. The prevalence has…

Osteoarthritis (OA) and rheumatoid arthritis (RA) are both inflammatory disorders that affect the cartilage and the lining of the joints, respectively. The Cleveland Clinic indicates that osteoarthritis is the most prevalent form of arthritis in the United States. It affects more than 70% of adults between 55 and 78 years of age, more commonly affecting women than men. The earliest symptoms of OA are joint stiffness, pain, and swelling. It is most common in the knee, hip, spine, and hands. Activity and…